multipl
research
identifi
new
virus
caus
acut
respiratori
diseas
ard
pharyng
conjunct
pneumon
soon
afterward
virus
recogn
relat
group
virus
given
present
name
adenovirus
adenovirus
often
caus
respiratori
ill
among
us
militari
traine
children
adenovirus
recogn
infect
mani
traine
requir
hospit
median
attack
rate
traine
rang
per
month
affect
northern
midwestern
us
militari
base
per
month
post
south
west
traine
unit
lost
ill
within
period
mani
hospit
restart
train
adenovirus
also
recogn
caus
much
instanc
gastroenter
infant
children
instanc
pneumonia
among
hospit
children
adenoviru
morbid
sever
lead
death
especi
young
children
transplant
recipi
immunocompromis
patient
search
vaccin
adenovirus
driven
adenoviru
morbid
among
militari
traine
disrupt
militari
train
medic
care
cost
seri
misstart
militari
recruit
began
routin
receiv
live
oral
entericco
vaccin
adenoviru
type
safe
effect
except
adenoviru
morbid
markedli
control
howev
sole
manufactur
vaccin
ceas
product
vaccin
store
deplet
us
militari
traine
experienc
larg
outbreak
adenoviru
diseas
death
remind
public
health
offici
impact
adenovirus
one
comprehens
studi
russel
colleagu
document
attack
rate
among
suscept
militari
recruit
week
train
import
pathogen
emphas
recent
emerg
multipl
novel
strain
subsequ
epidem
death
caus
human
adenovirus
classic
group
seven
speci
g
contain
mani
uniqu
type
multipl
genotyp
often
determin
restrict
enzym
digest
etc
howev
nomenclatur
classif
system
undergo
chang
intern
committe
taxonomi
virus
ad
genu
prefix
eg
human
adenoviru
becom
human
mastadenoviru
number
investig
addit
argu
time
move
away
neutral
hemagglutin
assay
determin
serotyp
chiefli
use
genet
classif
approach
virologist
use
larg
dna
sequenc
comparison
describ
mani
novel
adenoviru
type
although
approach
met
debat
matter
adenoviru
nomenclatur
classif
system
agre
upon
clear
adenovirus
affect
organ
system
individu
adenoviru
type
often
differ
tissu
tropism
lead
specif
sign
symptom
tabl
endem
respiratori
adenoviru
children
although
children
becom
infect
mani
common
adenovirus
earli
life
approxim
infect
result
diseas
isol
studi
indic
preval
type
detect
often
manifest
pharyng
bronchiti
bronchiol
croup
pneumonia
incid
adenoviru
diseas
higher
late
winter
spring
earli
summer
sex
equal
affect
gland
may
observ
epidem
keratoconjunct
ekc
associ
rare
type
addit
isol
genit
tract
young
adult
ekc
possibl
sexual
transmiss
consid
numer
epidem
ekc
associ
ophthalmolog
practic
spread
contamin
ophthalm
solut
finger
instrument
implic
hemorrhag
cystiti
hemorrhag
cystiti
syndrom
children
caus
adenoviru
infect
case
unit
state
japan
although
specif
rout
spread
unknown
frequent
isol
adenovirus
boy
two
three
time
often
affect
girl
clinic
find
includ
gross
hematuria
day
durat
dysuria
microscop
hematuria
urinari
frequenc
last
day
longer
viremia
structur
abnorm
found
adenovir
antigen
exfoli
bladder
epitheli
cell
demonstr
immunofluoresc
case
acut
hemorrhag
cystiti
renal
bone
marrow
transplant
increasingli
report
well
speci
b
adenovirus
first
isol
renal
transplant
recipi
neither
associ
symptom
hemorrhag
cystiti
gastroenter
adenovirus
also
recogn
caus
wateri
diarrhea
fever
preval
strain
detect
among
immunocompromis
associ
one
outbreak
cluster
acut
gastroenter
strain
often
requir
special
cell
line
cultur
may
demonstr
cytopath
effect
electron
micrographi
special
assay
often
necessari
studi
numer
outbreak
describ
adenovirus
may
account
infant
diarrhea
rare
acut
manifest
number
case
outbreak
report
document
unusu
manifest
human
adenoviru
infect
occur
frequent
among
children
although
studi
recogn
recombin
document
caus
signific
ard
morbid
among
militari
traine
china
typic
ard
febril
diseas
symptom
sore
throat
fever
cough
coryza
rhinorrhea
headach
chest
pain
extens
lung
physic
examin
reveal
rale
rhonchi
littl
evid
consolid
chest
radiographi
often
show
patchi
interstiti
infiltr
princip
lower
lung
field
symptom
last
day
infect
often
selflimit
occasion
death
occur
rout
transmiss
thought
includ
direct
contact
aerosol
viru
inhal
lung
viru
isol
oropharynx
week
exposur
syndrom
character
pharyng
conjunct
spike
fever
first
describ
associ
swim
caus
subsequ
link
insuffici
chlorin
one
eye
affect
diarrhea
coryza
tonsillar
exud
lymphadenopathi
may
observ
frequent
identifi
type
type
also
associ
pharyngoconjunctiv
fever
diseas
associ
summer
camp
swim
pool
lake
occur
children
young
adult
often
spread
famili
member
incub
period
day
viru
may
isol
pool
water
littl
bacteri
superinfect
perman
damag
eye
epidem
conjunct
adult
caus
adenovirus
first
describ
shipyard
eye
diseas
observ
industri
set
shipbuild
took
place
probabl
transmit
inadequ
infect
control
practic
worker
sought
care
chemic
irrit
minor
trauma
paint
rust
chip
diseas
incub
time
day
character
conjunct
edema
eye
pain
photophobia
lacrim
superfici
eros
subepitheli
infiltr
cornea
may
occur
preauricular
lymph
gland
swell
involv
cervic
submaxillari
lymph
thank
often
molecular
techniqu
human
adenovirus
associ
number
chronic
diseas
condit
includ
chronic
airway
obstruct
pulmonari
dysplasia
myocard
cardiomyopathi
although
result
studi
mix
intrigu
seri
human
anim
studi
associ
number
human
adenoviru
type
obes
virolog
human
adenovirus
nonenvelop
doublestrand
dna
virus
belong
genu
mastadenoviru
famili
adenovirida
classifi
speci
ag
hemagglutin
properti
serotyp
hors
rabbit
antisera
tabl
differ
strain
within
serotyp
distinguish
wholegenom
restrictionenzym
digest
pattern
howev
type
serum
sampl
difficult
acquir
sequenc
cost
decreas
virologist
consid
full
genom
sequenc
modern
accur
method
detect
uniqu
strain
describ
mani
uniqu
adenoviru
type
adenovirus
consid
larg
virus
estim
diamet
approxim
virus
icosahedr
capsid
shell
made
hexon
base
penton
base
fiber
associ
penton
base
fig
four
minor
protein
iiia
vi
viii
inconsist
adenoviru
implic
possibl
fetal
pathogen
adenoviru
infect
among
children
associ
sudden
infant
death
enceph
meningoenceph
cerebr
edema
acut
flaccid
paralysi
pertussislik
syndrom
mononucleosislik
syndrom
neonat
dissemin
infect
among
adult
adenoviru
infect
associ
toxic
shocklik
syndrom
enceph
genit
lesion
orchiti
urethr
cervic
nosocomi
transmiss
suscept
healthcar
worker
patient
report
like
relat
long
period
viral
shed
among
adenovirusinfect
immunocompromis
host
possibl
aerosol
viru
fomit
transmiss
hospit
set
complic
adenovirus
implic
opportunist
agent
patient
immun
defici
state
patient
aid
patient
receiv
cancer
chemotherapi
bone
marrow
transplant
recipi
patient
undergo
solid
organ
transplant
patient
prone
pneumonia
dissemin
adenovir
infect
also
develop
parot
urinari
tract
diseas
number
recent
describ
type
recov
peopl
aid
review
bone
marrow
recipi
period
indic
adenoviru
infect
occur
patient
higher
incid
children
adult
vs
common
type
identifi
hierholz
report
adenoviru
infect
immunocompromis
patient
pneumonia
associ
case
fatal
rate
high
compar
among
immunocompet
host
pneumonia
radiograph
adenovirusinfect
patient
often
demonstr
patchi
interstiti
infiltr
usual
lower
lung
field
origin
nonhuman
primat
henc
virologist
recent
review
probabl
adenovirus
may
zoonot
adenoviru
type
determin
oncogen
anim
transform
cell
line
oncogen
observ
human
hybrid
genet
recombin
multipl
strain
adenoviru
may
occur
sometim
recombin
strain
emerg
novel
adenoviru
strain
lead
epidem
number
recent
exampl
report
medic
literatur
depend
rout
inocul
type
viru
immun
state
host
adenovirus
caus
diseas
asymptomat
infect
respiratori
infect
presum
result
inhal
aerosol
viru
wherea
ocular
infect
gastroenter
nosocomi
infect
may
aris
fomit
water
fecalor
contact
reactiv
latent
adenoviru
also
believ
occur
tonsil
remov
surgic
may
adenovirus
isol
tissu
suggest
virus
may
remain
latent
state
year
viru
also
isol
lymphocyt
kidney
blood
cerebrospin
fluid
bodi
organ
lung
extens
patholog
found
microscop
necrosi
tracheal
bronchial
epithelium
acidophil
intranuclear
inclus
seen
bronchial
epitheli
cell
addit
basophil
mass
cell
surround
clear
halo
may
indic
aggreg
viral
materi
mononuclear
infiltr
rosett
format
focal
necrosi
mucou
gland
characterist
seen
three
type
interact
adenoviru
infect
cell
occur
lytic
infect
may
take
place
viru
complet
entir
replic
cycl
progeni
virus
per
cell
produc
actual
infecti
second
type
interact
chronic
latent
infect
small
amount
viru
produc
inappar
infect
result
viral
shed
gastrointestin
tract
may
occur
year
fact
reactiv
latent
infect
like
explain
much
adenoviru
diseas
sever
compromis
correspondingli
monitor
viral
load
stool
transplant
patient
predict
dissemin
diseas
use
guid
antivir
therapi
addit
aerosol
intestin
shed
respiratori
viru
import
factor
consid
prevent
nosocomi
spread
hospit
chronic
care
home
persist
infect
report
epitheli
cell
monkey
lymphoid
cell
thought
reservoir
persist
infect
third
type
interact
oncogen
transform
wherebi
viral
dna
integr
host
genom
replic
cellular
host
dna
earli
step
viral
cycl
occur
infecti
virion
produc
gene
adenovirus
express
cell
nucleu
two
phase
earli
e
preced
viral
dna
replic
late
earli
gene
encod
protein
function
thwart
immunosurveil
especi
transcript
unit
late
gene
primarili
encod
viral
structur
protein
function
protein
includ
induct
dna
synthesi
quiescent
cell
immort
primari
cell
cooper
activ
ra
protein
transactiv
delay
earli
gene
induct
repress
sever
cellular
gene
induct
apoptosi
protein
modul
sensit
adenovirusinfect
cell
tumor
necrosi
factor
tnf
ix
add
complex
capsid
penton
hexon
deriv
differ
viral
polypeptid
adenoviru
hexon
typespecif
speciesspecif
antigen
primarili
induc
speciesspecif
complementfix
antibodi
wherea
penton
especi
activ
hemagglutin
fiber
also
evok
typespecif
antibodi
vari
length
among
human
strain
sometim
absent
particular
anim
strain
genom
core
viru
compos
five
protein
v
vii
u
termin
protein
singl
molecul
linear
doublestrand
dna
molecular
weight
g
c
base
composit
human
viru
genom
rang
adenovirus
unusu
stabl
physic
chemic
agent
well
advers
ph
thu
surviv
long
period
outsid
host
make
avail
transmiss
other
destroy
heat
minut
uv
irradi
sodium
dodecyl
sulfat
chlorin
formalin
resist
ether
chloroform
adenovirus
replic
cell
nucleu
tend
hostspecif
howev
mount
evid
human
anim
exchang
adenovirus
simian
adenoviru
epidem
occur
among
nonhuman
primat
us
research
center
subsequ
infect
primat
caretak
evid
humantohuman
transmiss
report
document
recent
detect
distinct
adenoviru
nonhuman
primat
map
phylogenet
close
human
adenoviru
speci
human
infect
novel
avian
adenoviru
associ
avian
chlamydiosi
outbreak
hong
kong
final
also
import
recogn
thought
suspect
type
adenovirus
detect
varieti
specimen
includ
nasal
throat
secret
conjunctiv
scrape
swab
stool
blood
cerebrospin
fluid
biopsi
tissu
specimen
specimen
collect
earli
ill
ship
promptli
dri
ice
prompt
test
possibl
swab
fresh
tissu
specimen
must
transport
appropri
viral
transport
media
wherea
fluid
sampl
like
urin
stool
cerebrospin
fluid
dilut
transport
media
cultur
nonsteril
specimen
treat
antibiot
prior
inocul
stool
specimen
brought
suspens
buffer
salin
clarifi
lowspe
centrifug
blood
cultur
molecular
test
collect
anticoagul
prevent
clot
serum
separ
clot
blood
sampl
use
serolog
diagnosi
see
cell
cultur
biolog
amplif
cell
cultur
offer
sensit
method
adenoviru
detect
monitor
cytopath
effect
cpe
adenovirus
hostspecif
isol
human
adenovirus
easili
accomplish
human
cell
human
adenovirus
success
isol
cell
cultur
sever
diploid
continu
cell
line
includ
hela
kb
commerci
mix
cell
line
cell
reportedli
give
good
overal
recoveri
produc
typic
cpe
howev
fastidi
enter
adenovirus
except
effici
recoveri
strain
requir
secondari
hek
human
embryo
kidney
cell
line
primari
isol
cpe
may
develop
slowli
monolay
inocul
cell
necessit
sever
subpassag
becom
visibl
infect
cell
becom
round
enlarg
refractil
aggreg
irregular
grapelik
cluster
incub
blind
passag
recommend
rapid
procedur
cultur
identif
adenoviru
shell
vial
techniqu
cell
monolay
prepar
glass
vial
multiwel
plastic
cultur
plate
inocul
clinic
specimen
centrifug
stain
day
incub
commerci
monoclon
antibodi
cell
cultur
declin
routin
diagnost
method
detect
identif
human
adenovirus
result
cost
delay
antigen
molecular
detect
techniqu
supplant
cultur
mani
laboratori
see
howev
direct
detect
method
offer
import
diagnost
benefit
cultur
mean
avail
obtain
suffici
viru
immunotyp
assess
viru
suscept
antivir
identifi
infecti
viru
clinic
environment
specimen
electron
immunoelectron
microscopi
commonli
use
detect
identifi
fastidi
adenovirus
stool
specimen
young
children
therebi
establish
associ
acut
gastroenter
method
still
use
local
viru
cell
biopsi
autopsi
specimen
confirm
diseas
associ
studi
diseas
patholog
antigen
assay
detect
adenoviru
antigen
protein
accomplish
react
virusspecif
polyclon
monoclon
antibodi
label
variou
report
system
exampl
includ
enzym
immunoassay
immunofluoresc
assay
timeresolv
fluoroimmunoassay
latex
agglutin
assay
use
detect
adenoviru
protein
directli
clinic
specimen
key
inflammatori
cytokin
antivir
properti
none
gene
requir
adenoviru
replic
cultur
cell
sever
protein
k
k
k
inhibit
tnf
cytolysi
major
function
tnf
may
prevent
viral
replic
inhibit
tnf
viral
protein
may
signific
mechan
pathogenesi
anoth
signific
protein
gp
k
glycoprotein
locat
endoplasm
reticulum
form
complex
class
antigen
major
histocompat
complex
mhc
prevent
cell
kill
cytotox
lymphocyt
cotton
rat
anim
model
use
ginsberg
colleagu
ginsberg
princ
studi
pathogenesi
caus
pneumonia
similar
seen
human
two
phase
infect
seen
initi
phase
character
infiltr
monocyt
neutrophil
later
phase
associ
infiltr
lymphocyt
patholog
seem
reflect
respons
host
immun
defens
viral
infect
gp
k
markedli
reduc
transport
class
mhc
surfac
infect
cell
imped
attack
cytotox
cell
known
earli
gene
requir
induc
complet
pathogenesi
adenoviru
infect
cotton
rat
although
sever
cytokin
elabor
first
day
infect
cotton
rat
model
major
role
pathogenesi
steroid
almost
complet
elimin
pneumon
inflammatori
respons
infect
patholog
caus
latent
infect
adenovirus
link
chronic
obstruct
pulmonari
diseas
copd
suggest
childhood
viral
diseas
repres
independ
risk
factor
copd
adenovir
protein
stimul
transcript
mani
heterolog
viral
cellular
gene
protein
abil
interact
dna
bind
domain
sever
cellular
transcript
factor
activ
wide
varieti
gene
adenovir
genom
found
present
lung
patient
copd
control
subject
protein
express
epitheli
cell
human
lung
tissu
increas
express
sever
gene
import
control
inflammatori
process
may
contribut
pathogenesi
copd
event
describ
may
amplifi
airway
inflamm
associ
cigarett
smoke
isol
clone
protein
adenoviru
receptor
mediat
attach
infect
group
b
virus
may
facilit
develop
new
strategi
limit
diseas
caus
adenovirus
common
receptor
refer
car
protein
identifi
receptor
coxsacki
b
viru
adenovirus
recent
anoth
receptor
desmoglein
identifi
strain
adenovir
infect
gener
diagnos
clinic
ground
alon
clinic
sign
symptom
infect
variabl
often
resembl
caus
microorgan
tradit
laboratori
support
qualifi
personnel
necessari
accur
diagnos
adenovirus
infect
consider
includ
specimen
type
time
collect
storag
procedur
type
laboratori
test
perform
includ
serolog
assay
avail
newer
type
diagnost
assay
specimen
collect
optim
specimen
diagnosi
adenoviru
infect
depend
clinic
present
specif
hypervari
region
viru
genom
potenti
import
viru
strain
result
recombin
mutat
miss
mccarthi
colleagu
propos
molecular
type
algorithm
combin
examin
hexon
fiber
gene
restrict
enzym
analysi
rea
wholeviru
genom
use
identifi
genet
variant
serotyp
aid
epidemiolog
studi
outbreak
investig
extens
studi
use
rea
describ
number
novel
virus
thu
identifi
howev
rea
work
intens
depend
viru
isol
recov
genom
dna
requir
expertis
perform
interpret
therefor
restrict
experienc
laboratori
classic
next
gener
sequenc
technolog
increasingli
use
obtain
full
genom
sequenc
human
adenovirus
genom
sequenc
avail
human
adenoviru
prototyp
type
sequenc
newli
identifi
genom
variant
routin
place
public
domain
provid
refer
data
adenoviru
identif
new
whole
genomebas
character
system
adenovirus
consider
replac
immunotyp
design
new
adenoviru
type
serolog
assay
acut
adenoviru
infect
also
diagnos
serolog
demonstr
fourfold
greater
rise
antibodi
titer
pair
acutephas
convalescentphas
sera
first
acut
specimen
collect
earli
possibl
onset
ill
convalesc
specimen
collect
week
later
serolog
test
adenovirus
includ
complement
fixat
cf
hi
sn
indirect
immunofluoresc
enzym
immunoassay
eia
classic
cf
test
measur
adenovirusgroup
specif
antibodi
though
wide
use
lack
sensit
eia
also
measur
adenoviru
groupspecif
antibodi
sensit
cf
test
readili
autom
therefor
wide
use
today
hi
sn
assay
also
sensit
cf
measur
typespecif
antibodi
suitabl
routin
diagnosi
reagent
commerci
avail
although
valuabl
outbreak
investig
essenti
seropreval
vaccin
efficaci
studi
serolog
rare
use
today
clinic
diagnosi
inconveni
serum
collect
delay
need
obtain
convalesc
serum
current
fdaapprov
treatment
prophylaxi
therapi
adenoviru
infect
numer
offlabel
therapeut
case
case
seri
report
result
mix
control
prospect
therapeut
studi
studi
prophylaxi
adenoviru
infect
without
good
effect
howev
maisch
colleagu
found
posit
effect
intraven
immunoglobulin
therapi
patient
adenovirusassoci
inflammatori
cardiomyopathi
studi
suggest
may
benefici
effect
ekc
viral
cardiomyopathi
recent
adopt
transfer
adenovirusspecif
tcell
explor
success
reserv
immunocompromis
patient
respond
antivir
therapi
offlabel
antivir
use
report
antivir
ribavirin
cidofovir
ganciclovir
acyclovir
vidarabin
also
disappoint
ribavirin
cidofovir
use
often
enough
worthi
discuss
nebul
ribavirin
use
success
two
children
pneumonia
caus
adenoviru
intraven
ribavirin
identifi
viru
isol
immunoassay
simpl
perform
less
costli
provid
result
quickli
cultur
molecular
test
gener
less
sensit
immunofluoresc
assay
often
use
clinic
diagnost
laboratori
rapid
identif
adenoviru
cell
unfrozen
specimen
pointofcar
antigen
immunoassay
rapid
adenoviru
detect
immunohistolog
stain
adenoviru
antigen
biopsi
autopsi
specimen
still
common
use
molecular
assay
molecular
method
rapidli
replac
classic
cultur
antigen
detect
diagnosi
adenoviru
infect
pcr
assay
particular
becom
popular
diagnost
altern
virus
offer
potenti
rapid
sensit
detect
easili
tailor
speciesspecif
typespecif
identif
describ
pcr
assay
use
adenoviru
groupspecif
primer
individu
combin
assay
multipl
human
pathogen
proven
compar
better
cell
cultur
immunodiagnost
method
detect
adenovirus
clinic
sampl
sever
commerci
multiplex
assay
respiratori
pathogen
includ
adenoviru
clear
us
food
drug
administr
fda
clinic
diagnost
use
use
quantit
realtim
pcr
assay
ad
benefit
allow
monitor
adenoviru
level
use
predict
patient
prognosi
manag
chemotherapi
monitor
efficaci
antivir
therapi
adenoviru
type
assay
detect
identif
adenovirus
speci
type
accomplish
varieti
immunolog
molecular
method
support
outbreak
investig
patient
clinic
manag
exampl
adenoviru
infect
bone
marrow
lung
transplant
recipi
rapidli
fatal
patient
interest
healthcar
provid
determin
speci
type
infect
adenoviru
sensit
specif
antivir
therapi
also
import
learn
adenoviru
repres
communityacquir
strain
healthcareacquir
strain
donorassoci
strain
reactiv
latent
viru
effort
identifi
adenovirus
led
discoveri
crossspeci
infect
simian
adenovirus
acquir
nonhuman
primat
reservoir
serum
neutral
sn
use
defin
hyperimmun
anim
antisera
gold
standard
method
use
classifi
human
adenoviru
type
sn
target
typespecif
neutral
epitop
adenoviru
hexon
fiber
protein
lesser
extent
penton
protein
hemagglutin
inhibit
hi
also
use
immunotyp
adenovirus
hi
target
typespecif
epitop
adenoviru
fiber
protein
use
combin
sn
identifi
hexonfib
recombin
virus
immunotyp
method
requir
refer
antisera
difficult
obtain
standard
often
difficult
interpret
molecular
method
gener
replac
immunotyp
rapid
routin
adenoviru
type
numer
molecular
method
speci
typespecif
identif
adenovirus
describ
includ
convent
realtim
pcr
assay
use
speciesspecif
typespecif
primer
probe
pcr
amplif
coupl
restrict
endonucleas
analysi
microarray
mass
spectrometri
increasingli
pcrcoupl
sequencebas
type
strategi
target
hypervari
region
adenoviru
hexon
fiber
gene
sever
commerci
assay
market
use
pcr
identifi
human
adenoviru
speci
molecular
type
strategi
often
focu
younger
year
person
chronic
diseas
person
infect
multipl
rare
strain
increas
risk
sever
clinic
diseas
similarli
begin
chile
uruguay
argentina
experienc
emerg
novel
strain
supplant
endem
strain
among
pediatr
patient
strain
associ
longer
hospit
higher
patient
temperatur
greater
oxygen
requir
secondari
attack
rate
among
sibl
explain
adenoviru
mortal
similarli
first
detect
israel
spread
unit
state
sinc
associ
three
five
document
us
civilian
outbreak
least
one
militari
outbreak
outbreak
led
least
death
suggest
new
genotyp
virul
strain
report
iowa
displac
strain
recent
novel
genotyp
seldomdetect
strain
classifi
emerg
unit
state
spread
countri
caus
consider
morbid
death
differ
prototyp
strain
markedli
greater
epitheli
cell
bind
cell
cytotox
plaqu
morpholog
minor
mutat
fiber
knob
gene
note
virtual
children
adenoviru
infect
occasion
infect
sever
lead
death
addit
adenoviru
infect
quit
common
among
immunocompromis
often
associ
signific
morbid
adenoviru
epidem
often
occur
intens
care
unit
longterm
care
facil
instanc
novel
variant
caus
resid
age
rang
year
new
york
longterm
care
facil
becom
ill
hospit
die
nation
us
adenoviru
studi
author
found
risk
factor
sever
clinic
adenoviru
diseas
includ
age
younger
year
chronic
diseas
recent
transplant
infect
epidem
among
militari
popul
especi
adenoviru
vaccin
avail
particularli
well
document
use
vaccin
us
militari
account
ard
among
hospit
recruit
also
occur
less
commonli
recruit
becam
infect
adenoviru
season
militari
personnel
experienc
lower
rate
outbreak
also
report
among
militari
recruit
china
finland
netherland
unit
kingdom
turkey
singapor
south
korea
diseas
characterist
adenovirus
vari
speci
type
see
tabl
reason
differ
well
understood
adenovirus
transmit
direct
contact
aerosol
viru
fecalor
rout
via
water
although
recent
data
suggest
human
may
simian
origin
novel
adenovirus
may
cross
speci
human
anim
human
thought
far
primari
reservoir
human
adenoviru
common
environ
adenoviru
transmiss
home
howev
high
rate
adenoviru
transmiss
reportedli
use
immunocompromis
patient
patient
hemorrhag
cystiti
dissemin
diseas
intraven
ribavirin
given
adult
blood
marrow
transplant
recipi
without
appreci
benefit
mix
report
may
explain
recent
find
human
adenovirus
speci
c
suscept
ribavirin
contrast
speci
human
adenoviru
appear
suscept
cidofovir
perhap
find
explain
better
result
antivir
drug
retrospect
studi
bone
marrow
transplant
recipi
treat
cidofovir
adenoviru
infect
success
outcom
howev
patient
cidofovirassoci
toxic
develop
new
experiment
oral
antivir
therapi
dna
virus
brincidofovir
formerli
show
great
promis
adenovirus
analog
cidofovir
cidofovir
renal
toxic
profil
current
brincidofovir
evalu
dna
virus
includ
adenovirus
award
fast
track
design
fda
approxim
childhood
adenoviru
infect
result
diseas
preval
detect
antibodi
studi
high
speci
c
usual
endem
acquir
earli
childhood
often
year
age
school
age
children
expos
sever
type
adenovirus
infect
caus
may
occur
later
age
mani
type
occur
sporad
epidem
mani
adenoviru
infect
subclin
asymptomat
especi
speci
convers
usual
caus
symptomat
respiratori
diseas
type
adenovirus
thought
endem
worldwid
schmitz
colleagu
summar
year
adenoviru
report
sent
world
health
organ
note
increas
preval
declin
preval
age
predilect
highli
signific
infant
speci
infant
small
children
speci
c
school
children
school
children
adult
adult
type
speci
b
e
predilect
male
observ
type
speci
b
c
summari
clinic
adenoviru
submiss
us
laboratori
period
reveal
preval
preval
preval
preval
explain
ill
among
children
author
note
increas
preval
time
even
though
type
adenoviru
found
throughout
world
sometim
mark
differ
observ
geograph
distribut
specif
genotyp
particular
note
distribut
genotyp
anecdot
suggest
genotyp
may
virul
competit
advantag
yet
clear
marker
increas
adenoviru
virul
identifi
lebeck
colleagu
report
clinic
isol
us
laboratori
restrict
enzym
digest
preval
type
newli
describ
strain
becam
preval
multivari
model
reveal
children
rate
reduct
hospit
ill
caus
adenovirus
even
low
rate
protect
report
save
armi
approxim
million
year
adenoviru
seed
lot
found
contamin
simian
viru
viru
oncogen
anim
licens
vaccin
rescind
although
caus
consider
concern
time
epidemiolog
studi
era
us
armi
male
veteran
show
evid
increas
risk
variou
cancer
plausibl
could
result
exposur
use
live
vaccin
ard
caus
investig
oral
administr
report
induc
high
antibodi
level
couch
colleagu
chanock
colleagu
demonstr
adenovirus
infect
gastrointestin
tract
produc
symptom
adult
find
led
administr
viru
vaccin
entericco
capsul
produc
asymptomat
intestin
infect
neutral
antibodi
mani
safeti
studi
perform
human
volunt
includ
administr
vaccin
separ
simultan
neutral
antibodi
elicit
asymptomat
infect
evidenc
recoveri
viru
rectal
specimen
initi
vaccin
viru
product
use
hek
cell
later
modifi
use
human
diploid
fibroblast
strain
primari
cell
suitabl
largescal
product
concern
contamin
human
pathogen
adenovirus
oncogen
anim
much
attent
given
safeti
studi
hamster
transform
cell
line
adenovirus
addit
field
trial
vaccin
conduct
parri
island
sc
great
lake
il
indic
vaccin
highli
protect
safe
antigen
show
evid
transmiss
among
militari
traine
vaccin
use
led
reduct
ard
rate
intrins
vaccin
efficaci
high
use
monotyp
vaccin
follow
appear
ard
caus
fort
dix
nj
armi
adenoviru
surveil
program
initi
identifi
agent
ard
assess
fluctuat
diseas
pattern
vaccin
could
develop
licens
numer
studi
address
oncogen
potenti
human
trial
vaccin
demonstr
safeti
infect
antigen
lack
communic
similar
observ
vaccin
addit
trial
indic
vaccin
given
simultan
decreas
immunogen
occur
mass
immun
suppress
diseas
numer
outbreak
militari
popul
unit
state
europ
led
initi
studi
use
prototyp
vaccin
safeti
immunogen
trial
trial
vaccin
also
conduct
goal
protect
children
howev
vaccin
product
never
pursu
begin
live
entericco
oral
vaccin
routin
administ
adenoviru
morbid
greatli
reduc
vaccin
licens
fda
produc
wyeth
laboratori
depart
defens
notifi
sole
produc
vaccin
wyeth
laboratori
inc
marietta
pa
would
stop
product
perman
begin
wyeth
repeatedli
notifi
depart
defens
need
negoti
contract
would
consid
renov
exist
vaccin
product
facil
contract
renegoti
bulk
vaccin
product
ceas
last
vaccin
place
occur
wherev
larg
group
suscept
peopl
gather
transmiss
rate
higher
children
institut
daycar
center
lower
socioeconom
group
enter
adenovirus
may
import
pathogen
daycar
set
epidem
associ
often
occur
associ
swim
activ
associ
transmiss
physician
offic
nosocomi
outbreak
adenoviru
keratoconjunct
report
accid
emerg
depart
major
eye
hospit
unit
kingdom
nosocomi
conjunct
pharyng
pneumonia
caus
adenovirus
note
hospit
intens
care
unit
increas
number
immunocompromis
patient
hospit
adenoviru
infect
becom
frequent
caus
sever
diseas
addit
reactiv
latent
infect
could
possibl
initi
nosocomi
outbreak
person
defici
cellmedi
immun
greatest
risk
advers
outcom
bone
marrow
transplant
recipi
especi
suscept
adenoviru
infect
death
rate
among
immunodefici
patient
pneumonia
may
high
chronic
diarrhea
patient
aid
often
diagnost
problem
prospect
studi
use
extens
diagnost
techniqu
duoden
jejun
rectal
biopsi
demonstr
patient
adenoviru
infect
although
civilian
experi
establish
requir
vaccin
epidem
natur
extens
morbid
experienc
militari
recruit
demonstr
overwhelm
need
adenoviru
vaccin
militari
use
one
wellstudi
typic
epidem
fort
dix
nj
exemplifi
requir
platoon
men
follow
prospect
week
basic
train
episod
respiratori
ill
requir
hospit
document
hospit
rate
ard
due
adenoviru
soldier
per
week
larg
basic
train
post
rate
translat
approxim
ard
admiss
per
week
devast
impact
militari
hospit
excess
medic
cost
fact
soldier
recycl
owe
lost
train
time
result
signific
econom
loss
militari
seriou
disrupt
train
schedul
led
administr
attempt
control
epidem
sleep
headtofoot
keep
militari
unit
separ
cohort
impact
adenoviru
infect
militari
led
develop
adenoviru
vaccin
year
ago
immunoglobulin
therapi
found
particularli
use
prevent
adenoviru
infect
among
militari
traine
modern
passiv
immun
strategi
may
prove
help
particular
recent
isol
adspecif
cell
stem
cell
donor
effect
treat
hematopoiet
stem
cell
transplant
recipi
develop
sever
adenoviru
nonrespons
antivir
first
adenoviru
vaccin
prototyp
inject
bival
vaccin
grown
monkey
kidney
cell
formalininactiv
safeti
test
small
trial
reduc
admiss
adenovirus
larg
trial
soldier
effect
reduc
hospit
trival
vaccin
also
includ
also
test
largescal
product
vaccin
lot
led
variat
antigen
result
lower
protect
isol
respect
although
preval
detect
markedli
declin
recent
year
russel
aggreg
number
adenoviru
infect
among
us
militari
traine
fluctuat
avail
vaccin
season
fig
winter
month
prevent
clinic
infect
document
realiz
detect
adenoviru
ill
greatli
underestim
true
clinic
diseas
russel
colleagu
posit
true
count
clinic
adenoviru
diseas
occur
camp
estim
case
per
year
would
prevent
adenoviru
vaccin
avail
realiz
prevent
morbid
lost
public
health
offici
insid
outsid
us
depart
defens
mani
call
reacquisit
use
vaccin
septemb
year
wyeth
announc
perman
cessat
product
adenoviru
vaccin
two
wide
public
adenovirusassoci
death
nonimmun
recruit
strongli
word
letter
institut
medicin
arm
forc
epidemiolog
board
expedit
contract
effort
induc
depart
defens
contract
product
adenoviru
vaccin
decis
resum
product
base
continu
low
preval
antibodi
peopl
come
militari
occurr
document
outbreak
vaccin
given
almost
year
experi
ard
outbreak
potent
adenoviru
vaccin
tablet
form
request
extens
expir
date
use
vaccin
septemb
march
rather
yearround
us
depart
defens
attempt
obtain
maximum
benefit
remain
suppli
vaccin
suppli
deplet
loss
manufactur
vaccin
mani
document
outbreak
ard
due
adenovirus
us
militari
train
center
first
record
epidem
took
place
aprilmay
fort
jackson
sc
laps
vaccin
administr
occur
logist
error
temporarili
interrupt
vaccin
product
identifi
etiolog
agent
unvaccin
soldier
experienc
hospit
rate
basic
train
numer
addit
outbreak
occur
us
militari
camp
caus
larg
number
hospit
spread
advanc
train
camp
result
nationwid
seropreval
survey
among
unimmun
us
armi
traine
confirm
lack
protect
neutral
antibodi
nearli
suscept
least
one
type
evalu
epidem
clinic
immunolog
risk
factor
adenoviru
infect
perform
subset
patient
demonstr
immun
low
new
recruit
risk
ill
higher
smoker
patient
pair
serum
sampl
collect
demonstr
fourfold
higher
increas
titer
infect
gray
colleagu
provid
concis
overview
populationbas
surveil
respiratori
diseas
four
us
militari
train
center
last
store
vaccin
deplet
octob
june
throat
cultur
symptomat
traine
yield
adenovirus
account
outer
layer
inact
excipi
protect
enter
coat
consist
cellulos
acet
phthalat
alcohol
aceton
castor
oil
fig
vaccin
tablet
also
contain
fd
c
yellow
aluminum
lake
dye
give
distinguish
yellow
color
teva
adenoviru
vaccin
contain
live
nonattenu
form
entericco
tablet
produc
similarli
wyeth
vaccin
describ
produc
final
vaccin
compos
two
tablet
one
tablet
one
tablet
design
pass
intact
stomach
releas
live
viru
intestin
entericco
tablet
contain
inner
core
tablet
contain
anhydr
lactos
microcrystallin
cellulos
polacrilin
potassium
magnesium
stearat
live
adenoviru
either
type
type
potenc
fewer
tissuecultur
infect
dose
log
tcid
per
tablet
outer
tablet
layer
contain
microcrystallin
cellulos
magnesium
stearat
anhydr
lactos
enter
coat
consist
cellulos
acet
phthalat
alcohol
aceton
castor
oil
tablet
also
contain
fd
c
yellow
aluminum
lake
dye
vaccin
white
tablet
vaccin
yellow
tablet
packag
separ
bottl
bottl
combin
singl
packag
tablet
administ
simultan
swallow
without
chew
vomit
diarrhea
may
interfer
vaccin
effect
vaccin
indic
militari
popul
shown
risk
ard
specif
adenoviru
type
repres
tablet
adenoviru
vaccin
routin
given
militari
recruit
us
coast
guard
cadet
along
numer
vaccin
first
day
enter
train
typespecif
neutral
antibodi
adenoviru
vaccin
produc
vaccin
traine
associ
protect
ard
interfer
immun
respons
adenoviru
vaccin
given
vaccin
identifi
administ
genom
analysi
wyeth
vaccin
strain
show
evid
attenu
contract
award
seed
virus
strain
wyeth
transfer
barr
laboratori
inc
part
teva
pharmaceut
industri
inc
fall
teva
vaccin
studi
phase
doubleblind
placebocontrol
trial
involv
armi
medic
traine
complet
us
armi
basic
train
among
subject
previous
expos
adenoviru
basic
train
enrol
seroposit
respect
trial
initi
seroneg
subject
select
vaccin
given
receiv
placebo
tablet
subject
final
followup
permit
day
particip
close
follow
cultur
symptom
diari
clinic
examin
period
evid
vaccin
reaction
adenovir
diseas
commonli
report
advers
event
vaccin
recipi
nasal
congest
dri
cough
sore
throat
headach
abdomin
pain
arthralgia
nausea
diarrhea
symptom
report
differ
vaccin
placebo
group
vaccin
viru
shed
stool
volunt
seroneg
respect
long
day
vaccin
day
vaccin
vaccin
recipi
seroconvert
seroconvert
random
doubleblind
placebocontrol
phase
iiiii
trial
vaccin
conduct
two
militari
train
facil
vaccin
placebo
administ
us
militari
traine
ratio
describ
vaccin
found
excel
efficaci
safeti
profil
similar
previous
manufactur
wyeth
vaccin
march
arduou
vaccin
develop
process
eight
like
prevent
adenovirusassoci
death
thousand
hospit
million
fund
teva
award
fda
licensur
vaccin
vaccin
indic
militari
personnel
age
year
age
contraind
person
pregnant
swallow
vaccin
tablet
without
chew
sever
reaction
vaccin
wyeth
vaccin
tablet
contain
live
virus
materi
ad
growth
mainten
virus
cell
pharmaceut
materi
humandiploid
fibroblast
cell
strain
use
viru
prepar
growth
maintain
minim
essenti
medium
eagl
solut
antibiot
neomycin
sulfat
gentamicin
sulfat
amphotericin
b
fetal
bovin
serum
sodium
bicarbon
harvest
viral
growth
freed
particul
materi
filtrat
dri
lyophil
dri
addit
use
preserv
viabil
process
tablet
viru
prepar
dilut
lactos
powder
use
wyeth
master
seed
virus
manufactur
process
similar
process
wyeth
use
teva
produc
vaccin
teva
tablet
consist
three
layer
central
core
contain
least
log
tissu
cultur
infect
dose
tcid
lyophil
formul
adenoviru
mix
anhydr
lactos
microcrystallin
cellulos
polacrilin
potassium
magnesium
stearat
sn
assay
valu
specif
viru
consid
protect
fourfold
rise
titer
consid
evid
infect
although
earli
vaccin
trial
conduct
among
civilian
teva
vaccin
use
group
healthi
militari
traine
militari
recruit
receiv
vaccin
exhibit
increas
resist
respiratori
diseas
caus
viru
number
major
wellcontrol
studi
soldier
perform
use
vaccin
reduc
ard
adenoviru
infect
recruit
field
trial
began
vaccin
trial
indic
protect
diseas
suscept
person
addit
found
two
vaccin
could
administ
simultan
without
interfer
loss
efficaci
result
use
vaccin
one
larg
air
forc
base
period
ard
caus
adenoviru
disappear
adenoviru
surveil
program
demonstr
combin
two
adenoviru
vaccin
highli
effect
control
epidem
ard
live
entericco
vaccin
administ
new
militari
recruit
success
control
ard
caus
adenovirus
phase
iii
doubleblind
placebocontrol
efficaci
trial
teva
vaccin
conduct
found
vaccin
effect
reduc
ard
two
year
reintroduct
teva
vaccin
credit
declin
militari
traine
adenoviru
case
prevent
hospit
year
durat
immun
persist
circul
antibodi
follow
immun
well
studi
adenoviru
vaccin
develop
protect
new
member
militari
recruit
respiratori
diseas
first
month
militari
servic
adenoviru
vaccin
effect
accomplish
object
immun
beyond
day
studi
four
studi
group
follow
inpati
outpati
episod
ill
vaccin
safeti
immunogen
trial
lackland
air
forc
base
tx
addit
placebo
group
one
group
receiv
three
vaccin
simultan
anoth
group
receiv
two
vaccin
simultan
last
group
receiv
one
vaccin
appreci
differ
note
inpati
outpati
experi
differ
group
studi
variou
live
adenoviru
vaccin
document
fecal
pharyng
shed
vaccin
viru
initi
oral
vaccin
develop
use
dri
viru
contain
entericco
capsul
found
effect
prevent
infect
origin
trial
vaccin
conduct
use
ml
dilut
pool
tcid
within
hard
gelatin
capsul
given
oral
time
disintegr
within
intestin
assay
roentgenograph
use
barium
sulfatecontain
capsul
vari
hour
two
small
dose
rang
studi
use
vaccin
capsul
suggest
type
nearli
seroconvers
achiev
approxim
tcid
per
capsul
doserang
studi
use
three
dose
tcid
tcid
less
tcid
per
capsul
antibodi
respons
highest
dose
respons
intermedi
dose
respons
lowest
dose
anoth
studi
evalu
respons
vaccin
given
individu
dose
tcid
tcid
simultan
vaccin
dose
decreas
immunogen
vaccin
given
vaccin
mid
wyeth
laboratori
took
product
adenoviru
vaccin
convert
entericco
tablet
current
licens
teva
vaccin
store
shelf
life
month
oral
adenoviru
vaccin
recipi
routin
shed
viru
fecal
potenti
continu
week
wyeth
vaccin
recipi
develop
neutral
humor
antibodi
immunoglobulin
ig
g
igm
iga
soldier
free
preexist
antibodi
averag
develop
neutral
antibodi
level
greater
fewer
demonstr
complementfix
antibodi
neutral
antibodi
respons
detect
week
vaccin
gener
antibodi
titer
less
titer
achiev
natur
infect
local
secretori
iga
antibodi
induc
oral
vaccin
reinfect
respiratori
tract
possibl
usual
mild
asymptomat
sinc
viremia
viruria
could
occur
patient
febril
diseas
invas
beyond
mucos
surfac
could
import
pathogenesi
diseas
infect
serumneutr
antibodi
produc
result
vaccin
may
prevent
typic
febril
diseas
associ
natur
infect
local
iga
antibodi
could
produc
experiment
intranas
inocul
vaccin
liquid
phase
iii
studi
teva
oral
vaccin
show
subject
seroconvert
day
postvaccin
phase
iii
studi
vaccin
document
seroconvers
cellular
respons
wyeth
vaccin
well
studi
howev
cellular
immun
respons
adenovirusvector
vaccin
excel
high
risk
subsequ
infect
diseas
adenoviru
vaccin
recommend
use
militari
popul
risk
develop
ard
adenovirus
use
vaccin
recommend
popul
current
futur
studi
viru
transmiss
diseas
occurr
pediatr
popul
chronic
care
civilian
institut
set
highlevel
healthcar
organ
colleg
may
identifi
potenti
indic
adenoviru
vaccin
us
militari
began
routin
administ
vaccin
male
report
recruit
train
center
winter
month
incom
recruit
given
vaccin
within
hour
arriv
train
center
obtain
protect
earli
possibl
train
program
initi
women
given
vaccin
ard
outbreak
caus
adenovirus
never
document
among
militari
women
concern
possibl
administ
vaccin
women
pregnant
program
administ
vaccin
highrisk
winter
month
direct
control
rather
erad
ard
caus
adenovirus
schedul
late
spring
earli
fall
outbreak
occur
outbreak
prompt
us
armi
us
navi
adopt
polici
yearround
administr
adenoviru
vaccin
take
differ
cours
us
air
forc
stop
administr
adenoviru
vaccin
recruit
train
center
texa
adopt
program
surveil
use
vaccin
indic
militari
start
immun
protect
ard
caus
adenovirus
train
program
segreg
gender
separ
train
program
sinc
combin
lead
concern
risk
ard
caus
adenovirus
would
men
women
us
militari
regul
immun
requir
base
risk
vaccin
administ
simultan
armi
navi
marin
corp
recruit
air
forc
coast
guard
vaccin
administ
direct
appropri
author
regul
describ
precaut
taken
avoid
unintent
administr
vaccin
pregnanc
counsel
instruct
regard
possibl
pregnanc
within
month
follow
immun
respons
cessat
adenoviru
vaccin
product
armi
navi
marin
corp
modifi
polici
yearround
vaccin
administr
conserv
remain
vaccin
use
higherrisk
month
modifi
polici
direct
vaccin
given
arriv
militari
recruit
period
septemb
march
vaccin
stock
exhaust
teva
use
antibiot
viru
propag
step
vaccin
contraind
pregnant
women
immunocompromis
patient
person
outsid
target
age
rang
year
person
swallow
tablet
whole
person
allerg
vaccin
prevaccin
era
ard
adenovirus
caus
signific
morbid
militari
train
center
outbreak
transmiss
nonvaccin
studi
particip
although
recent
trial
teva
vaccin
demonstr
spars
transmiss
among
militari
personnel
possibl
transmiss
vaccin
viru
suscept
personnel
consid
week
receipt
modern
vaccin
navi
traine
hospit
fever
malais
dyspnea
day
receiv
vaccin
patient
die
hospit
day
diagnosi
pneumonia
base
isol
viru
cell
cultur
howev
possibl
time
determin
whether
infect
caus
wild
develop
vaccineinduc
immun
vaccin
strain
adenovirus
may
caus
sever
diseas
among
immunocompromis
person
hiv
first
discov
concern
grew
among
us
militari
public
health
offici
adenoviru
vaccin
might
caus
sever
diseas
among
hivinfect
militari
traine
subsequ
studi
conduct
among
hivinfect
uninfect
militari
traine
although
significantli
fewer
hivinfect
subject
respond
vaccin
soldier
without
hiv
infect
clinic
appar
advers
reaction
detect
respons
vaccin
difficult
defin
mani
vaccin
recipi
group
high
neutral
antibodi
titer
time
vaccin
sever
immunocompromis
person
might
inadvert
infect
adenoviru
vaccin
viru
fecal
shed
normal
vaccin
recipi
studi
live
oral
adenoviru
vaccin
never
subject
anim
reproduct
studi
lack
suitabl
anim
model
therefor
known
vaccin
potenti
caus
fetal
damag
given
pregnant
woman
affect
reproduct
capac
femal
militari
traine
screen
pregnanc
test
receiv
adenoviru
vaccin
recent
teva
vaccin
trial
four
subject
found
pregnant
receiv
vaccin
four
subject
deliv
healthi
babi
week
gestat
unusu
morbid
among
pregnant
vaccin
recipi
report
viru
may
shed
fecal
week
viru
may
spread
famili
member
close
contact
henc
vaccin
recipi
instruct
maintain
good
hygien
avoid
contact
children
younger
year
age
immunocompromis
pregnant
women
day
follow
vaccin
spread
vaccin
viru
well
studi
recent
phase
ii
trial
teva
vaccin
particip
follow
shed
day
period
fecal
shed
note
day
follow
vaccin
adenoviru
vaccin
indic
prevent
control
specif
adenovirusassoci
ard
popul
high
risk
exposur
high
level
suscept
excess
morbid
caus
ard
associ
cost
signific
concern
us
militari
number
costtobenefit
analys
perform
show
signific
benefit
use
vaccin
use
estim
cost
receipt
vaccin
use
vaccin
yearround
approxim
traine
per
year
radin
colleagu
estim
us
depart
defens
would
prevent
approxim
clinic
adenoviru
case
hospit
per
year
save
us
govern
approxim
million
per
year
train
medic
cost
solubl
viral
subunit
antigen
found
highli
immunogen
parenter
administr
anim
crystallin
hexon
fiber
antigen
shown
induc
neutral
antibodi
protect
human
volunt
challeng
addit
develop
antigen
potenti
vaccin
howev
adenoviru
vaccin
consist
solubl
viral
subunit
antigen
would
free
dna
could
allevi
fear
oncogen
potenti
adenovirus
advanc
molecular
biolog
permit
vivo
vitro
gene
transfer
mammalian
cell
use
variou
adenoviru
construct
genet
engin
adenovirus
alter
carri
gene
wide
array
pathogen
includ
influenza
viru
ebola
viru
middl
east
respiratori
syndromecoronaviru
introduc
gene
therapi
variou
chronic
diseas
adenoviru
vaccin
construct
research
quit
dynam
detail
descript
beyond
scope
textbook
howev
excel
review
publish
discuss
advantag
drawback
recombin
adenoviru
vaccin
strategi
extrem
costli
term
medic
care
requir
time
lost
train
routin
administr
vaccin
began
result
extrem
efficaci
costeffect
safe
immun
program
initi
vaccin
administ
highrisk
winter
month
occurr
spring
fall
outbreak
prompt
modif
program
administr
vaccin
yearround
except
period
ineffect
vaccin
thought
contamin
solvent
use
never
report
outbreak
ard
caus
us
militari
unit
receiv
vaccin
outbreak
ard
caus
occur
sporad
problem
administr
system
use
procur
vaccin
us
militari
result
adenoviru
vaccin
product
delay
began
spring
last
late
februari
one
outbreak
ard
caus
adenovirus
report
conjunct
product
delay
wyeth
laboratori
announc
would
longer
produc
adenoviru
vaccin
mani
us
depart
defens
differ
militari
servic
ask
vaccin
still
need
thought
improv
militari
barrack
modern
heat
ventil
aircondit
system
may
significantli
reduc
risk
transmiss
adenovirus
subsequ
diseas
suscept
peopl
assess
current
risk
hamper
lack
modern
seropreval
data
among
new
militari
entrant
lack
studi
adenoviru
carriag
transmiss
infect
diseas
vaccin
success
us
depart
defens
also
found
lost
capabl
perform
serolog
studi
adenoviru
infect
unfortun
loss
vaccin
adenovirusassoci
ard
increas
uniform
servic
includ
us
air
forc
vaccin
primari
mean
control
adenovirusinduc
ard
among
us
militari
traine
secondari
control
measur
includ
reduc
crowd
align
traine
bed
headtofoot
make
frequent
hand
wash
requir
increas
air
exchang
keep
contact
differ
cohort
recruit
minimum
cohort
although
intervent
like
frequent
hand
wash
caus
reduct
upper
respiratori
tract
infect
among
traine
numer
attempt
intervent
fell
far
short
effect
administ
adenoviru
vaccin
reduc
ard
